Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Liraglutide flexible dose injection once daily Liraglutide 1.8 mg or maximum tolerated dose	metformin with or without basal insulin; lifestyle: not reported	66	66	56
A2	Placebo Placebo	metformin with or without basal insulin; lifestyle: not reported	69	68	53

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Liraglutide flexible dose injection once daily A1	Placebo A2
age	mean (years)	14.6	14.6
age	sd (years)	1.7	1.7
asian	n	10	8
asian	percent	15.2	11.8
black	n	9	7
black	percent	13.6	10.3
bmi	mean (kg/m2)	34.6	33.3
bmi	sd (kg/m2)	10.9	7.4
diabetes duration	mean (years)	1.9	1.9
diabetes duration	sd (years)	1.7	1.3
female	n	41	42
hba1c	mean (percent)	7.9	7.7
hba1c	sd (percent)	1.4	1.3
hispanic	n	16	23
insulin use	n	15	10
insulin use	percent	22.7	14.7
other race american indian alaska native	n	2	1
other race american indian alaska native	percent	3.0	1.5
other race multiple	n	0	0
other race native hawaiian pacific islander	n	0	0
other race native hawaiian pacific islander	percent	0.0	0.0
other race other	n	3	7
other race other	percent	4.5	10.3
waist	mean (cm)	106.1	104.3
waist	sd (cm)	20.7	15.0
white	n	42	45
white	percent	63.6	66.2

Analyses this trial contributes to

HbA1c change
Children and adolescents with type 2 diabetes; weeks 12 to 40 (target week 26); descriptive only
HbA1c change
Children and adolescents with type 2 diabetes; weeks 40 to 64 (target week 52); descriptive only
HbA1c change
Children and adolescents with type 2 diabetes; weeks 40 to 64 (target week 52); descriptive only
HbA1c change
Children and adolescents with type 2 diabetes; weeks 12 to 40 (target week 26); descriptive only
Serious adverse events
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Serious adverse events
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Nausea
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Nausea
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Vomiting
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Vomiting
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Diarrhea
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Diarrhea
Children and adolescents with type 2 diabetes; longest follow-up; network meta-analysis
Constipation
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only
Constipation
Children and adolescents with type 2 diabetes; longest follow-up; descriptive only

Results

21 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (5 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
26	A1	change	-0.643 percent	0.215		66	treatment policy; full analysis; registry:outcomes
26	A1 vs A2	md	-1.058 percent	0.304	-1.653 to -0.464		treatment policy; full analysis; registry:outcomes
26	A2	change	0.415 percent	0.216		68	treatment policy; full analysis; registry:outcomes
52	A1	change	-0.732 percent	1.423		56	treatment policy; full analysis; registry:outcomes
52	A2	change	0.677 percent	1.523		52	treatment policy; full analysis; registry:outcomes

Serious adverse events (2 lines; O25)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				9 / 66	while on treatment; safety; registry:adverse_events
	A2	events				4 / 68	while on treatment; safety; registry:adverse_events

Discontinuation due to adverse events (2 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 66	not stated; randomized; registry:flow
	A2	events				1 / 69	not stated; randomized; registry:flow

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				19 / 66	while on treatment; safety; registry:adverse_events
	A2	events				9 / 68	while on treatment; safety; registry:adverse_events

Vomiting (2 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				17 / 66	while on treatment; safety; registry:adverse_events
	A2	events				6 / 68	while on treatment; safety; registry:adverse_events

Diarrhea (4 lines; O27C)

Arm	Statistic	Events / N	Detail
A1	events	15 / 66	while on treatment; safety; registry:adverse_events
A1	events	1 / 66	while on treatment; safety; registry:adverse_events
A2	events	11 / 68	while on treatment; safety; registry:adverse_events
A2	events	0 / 68	while on treatment; safety; registry:adverse_events

Constipation (4 lines; O27D)

Arm	Statistic	Events / N	Detail
A1	events	4 / 66	while on treatment; safety; registry:adverse_events
A1	events	0 / 66	while on treatment; safety; registry:adverse_events
A2	events	1 / 68	while on treatment; safety; registry:adverse_events
A2	events	0 / 68	while on treatment; safety; registry:adverse_events

Ellipse™

Design

Conduct and analysis

Arms

Baseline characteristics

Analyses this trial contributes to

Results